Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab.
Conditions
Interventions
Ianalumab
Locations
14
Belgium
Novartis Investigative Site
Roeselare, West-Vlaanderen, Belgium
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Ostrava, Poruba, Czechia
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Start Date
April 27, 2026
Primary Completion Date
August 30, 2030
Completion Date
August 30, 2030
Last Updated
April 13, 2026
NCT05070845
NCT06888960
NCT05002777
NCT06594146
NCT07421167
NCT07083739
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions